Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL268 Target Snapshot

Cathepsin K · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,936Compounds
324Assays
3Approved Drugs
3,252.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Cathepsin K shows late clinical disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P43235. Start with osteoporosis, then reuse UniProt P43235 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with osteoporosis, then reuse UniProt P43235 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
osteoporosis

Cathepsin K shows late clinical disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with osteoporosis because it currently carries late clinical support. Linked drugs include BALICATIB, ODANACATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cathepsin K as ChEMBL target CHEMBL268, mapped to UniProt P43235. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cathepsin K
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL268
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43235
Cathepsin K
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cathepsin K is the right protein anchor across sources, using UniProt P43235 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why osteoporosis is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCathepsin K
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP43235
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCathepsin K
UniProt AccessionP43235
Component TypeProtein
Sequence Length329 aa

Cathepsin K

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cathepsin K, mapped to UniProt P43235. Sequence length is 329 aa.

Mapped IDP43235
Review nameCathepsin K
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Cathepsin K shows late clinical disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
osteoporosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugBALICATIB
Linked drugODANACATIB
Late clinical Phase III
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugODANACATIB
Late clinical Phase III
postmenopausal osteoporosis
1 linked drug · 1 direct · 1 efficacy
Linked drugODANACATIB
Late clinical Phase III
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugODANACATIB
Clinical signal Phase II
osteoarthritis
1 linked drug · 1 direct · 1 efficacy
Linked drugODANACATIB
Clinical signal Phase II
osteoarthritis, knee
1 linked drug · 1 direct · 1 efficacy
Linked drugBALICATIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with osteoporosis because it currently carries late clinical support. Linked drugs include BALICATIB, ODANACATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseosteoporosis
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
6
Phase II
Assay Mix

Activity Type Distribution

IC502,326.0
KI926.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL386506 11.0 IC50 0.01 Preclinical
CHEMBL414530 10.96 IC50 0.011 Preclinical
CHEMBL374890 10.96 IC50 0.011 Preclinical
CHEMBL1651354 10.96 Ki 0.011 Preclinical
CHEMBL449096 10.89 IC50 0.013 Preclinical
CHEMBL480317 10.82 IC50 0.015 Preclinical
CHEMBL1651355 10.77 Ki 0.017 Preclinical
CHEMBL371420 10.72 Ki 0.019 Preclinical
CHEMBL218024 10.66 IC50 0.022 Preclinical
CHEMBL1651350 10.66 Ki 0.022 Preclinical
Distribution

pChEMBL Value Distribution

436
5.0
300
5.5
267
6.0
234
6.5
353
7.0
319
7.5
261
8.0
173
8.5
122
9.0
66
9.5
pChEMBL
Approved Drugs

Approved Drugs

BOCEPREVIR
CHEMBL218394
Approved 2011
Properties Compare Identifier
TELAPREVIR
CHEMBL231813
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

324
Total Assays
2,247
Tested Compounds
4
Assay Types
Binding — 313 assays, 2,247 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 292 2,138 6.9
cell-based format 11 25 7.0
assay format 9 84 6.6
subcellular format 1 0 —
ADME — 5 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 1 8.7
Toxicity — 5 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 1 7.7
Functional — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine